Assessment of Potential Interactions Between Methamphetamine and Selegiline

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-09-30

Study Completion Date

2002-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

NCT00089440

Amphetamine-Related Disorders

UNKNOWN PHASE1

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657

Amphetamine-Related Disorders

UNKNOWN PHASE1

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

NCT00265278

Amphetamine-Related Disorders

UNKNOWN PHASE1

Methamphetamine Abuse Treatment in Patients With AIDS - 1

NCT00000321

Substance-Related Disorders

COMPLETED PHASE4

Infusion Laboratory: Protocol 1 - Selegeline - 2

NCT00000337

Cocaine-Related Disorders

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg \& 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amphetamine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Selegiline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
* Be able to verbalize understanding of consent form; provide written informed consent